WELLESLEY, Mass.--(BUSINESS WIRE)--Lumicell, Inc., a technology leader in the field of image-guided cancer surgery, announced today that management will participate in two upcoming September meetings, including:
- The 2nd International Prostate Cancer Symposium and Inaugural World Congress of Urologic Oncology being held September 7 - 9, 2017 in New York, NY. Felix Geissler, MD, PhD, Chief Medical Officer of Lumicell, will be on site at the Lumicell exhibit booth to describe the benefits of the LUM System to leading cancer surgeons, academics and industry professionals in the field of prostate cancer.
- Institute for Biomedical Entrepreneurship (IBE) Certificate Session being held September 13 - 17, 2017 in Cambridge, MA. Kelly Londy, Chief Executive Officer of Lumicell will present as a guest faculty member in a session titled “Scientific Validation, Scientific Replication and the Commercial Pathway” on Friday, September 15 from 1:45 to 3:00 p.m.
“We are delighted to represent Lumicell at these important industry meetings and look forward to providing further updates on our progress with the LUM System in the coming weeks,” said Kelly Londy, Chief Executive Officer of Lumicell.
About Lumicell, Inc.
Lumicell is a technology leader in the field of image-guided cancer surgery. The company is developing a novel system that enables real-time detection of tumor tissue in patients so that no cancer cells are left behind during surgery. The LUM System includes three integrated components: a fluorescent optical contrast agent that is cancer- and immuno-activated, a novel hand-held imaging device that instantly scans the cavity walls to view the fluorescent cells with single-cell detection, and proprietary decision software that displays the image instantly on a monitor to guide surgical removal of cancerous tissue. The unprecedented ability to see and remove cancer cells remaining in the cavity – beyond the margin of the specimen – during the initial surgery has the potential to significantly improve surgical outcomes and reduce healthcare costs by eliminating the need for repeat surgeries. Lumicell is investigating the LUM System in patients undergoing surgery for breast cancer, prostate cancer, colorectal, esophageal and pancreatic cancers. Additional future indications are planned to include surgeries for lung, ovarian, and brain cancers. For more information, please visit www.lumicell.com.